Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
Tao Y, Sun XS, Pointreau Y, Le Tourneau C, Sire C, Kaminsky MC, Coutte A, Alfonsi M, Calderon B, Boisselier P, Martin L, Miroir J, Ramee JF, Delord JP, Clatot F, Rolland F, Villa J, Magne N, Elicin O, Gherga E, Nguyen F, Lafond C, Bera G, Calugaru V, Geoffrois L, Chauffert B, Damstrup L, Crompton P, Ennaji A, Gollmer K, Nauwelaerts H, Bourhis J. Tao Y, et al. Among authors: lafond c. Eur J Cancer. 2023 Apr;183:24-37. doi: 10.1016/j.ejca.2022.12.015. Epub 2023 Jan 9. Eur J Cancer. 2023. PMID: 36796234 Free article. Clinical Trial.
Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).
Tao Y, Aupérin A, Sun X, Sire C, Martin L, Coutte A, Lafond C, Miroir J, Liem X, Rolland F, Even C, Nguyen F, Saada E, Maillard A, Colin-Batailhou N, Thariat J, Guigay J, Bourhis J. Tao Y, et al. Among authors: lafond c. Eur J Cancer. 2020 Dec;141:21-29. doi: 10.1016/j.ejca.2020.09.008. Epub 2020 Oct 24. Eur J Cancer. 2020. PMID: 33125944 Free article. Clinical Trial.
Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial.
Tao Y, Auperin A, Blanchard P, Alfonsi M, Sun XS, Rives M, Pointreau Y, Castelli J, Graff P, Wong Hee Kam S, Thariat J, Veresezan O, Heymann S, Renard-Oldrini S, Lafond C, Cornely A, Casiraghi O, Boisselier P, Lapeyre M, Biau J, Bourhis J. Tao Y, et al. Among authors: lafond c. Radiother Oncol. 2020 Sep;150:18-25. doi: 10.1016/j.radonc.2020.05.021. Epub 2020 May 15. Radiother Oncol. 2020. PMID: 32417348 Free article. Clinical Trial.
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Among authors: lafond c. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.
Tao Y, Biau J, Sun XS, Sire C, Martin L, Alfonsi M, Prevost JB, Modesto A, Lafond C, Tourani JM, Miroir J, Kaminsky MC, Coutte A, Liem X, Chautard E, Vauleon E, Drouet F, Ruffier A, Ramee JF, Waksi G, Péchery A, Wanneveich M, Guigay J, Aupérin A, Bourhis J. Tao Y, et al. Among authors: lafond c. Ann Oncol. 2023 Jan;34(1):101-110. doi: 10.1016/j.annonc.2022.10.006. Epub 2022 Oct 28. Ann Oncol. 2023. PMID: 36522816 Free article. Clinical Trial.
Adaptive radiotherapy for head and neck cancer.
Castelli J, Simon A, Lafond C, Perichon N, Rigaud B, Chajon E, De Bari B, Ozsahin M, Bourhis J, de Crevoisier R. Castelli J, et al. Among authors: lafond c. Acta Oncol. 2018 Oct;57(10):1284-1292. doi: 10.1080/0284186X.2018.1505053. Epub 2018 Oct 5. Acta Oncol. 2018. PMID: 30289291 Review.
[Oropharyngeal cancer].
Lafond C, Pointreau Y, Debelleix C, Denis F, Calais G, Bourhis J, Thariat J. Lafond C, et al. Cancer Radiother. 2010 Nov;14 Suppl 1:S34-42. doi: 10.1016/S1278-3218(10)70006-8. Cancer Radiother. 2010. PMID: 21129668 French.
[Radiotherapy of larynx cancers].
Pointreau Y, Lafond C, Legouté F, Trémolières P, Servagi-Vernat S, Giraud P, Maingon P, Calais G, Lapeyre M. Pointreau Y, et al. Among authors: lafond c. Cancer Radiother. 2016 Sep;20 Suppl:S131-5. doi: 10.1016/j.canrad.2016.07.018. Epub 2016 Aug 9. Cancer Radiother. 2016. PMID: 27521037 French.
[Radiotherapy of hypopharynx cancers].
Pointreau Y, Lafond C, Trémolières P, Legouté F, Servagi-Vernat S, Giraud P, Maingon P, Calais G, Lapeyre M. Pointreau Y, et al. Among authors: lafond c. Cancer Radiother. 2016 Sep;20 Suppl:S126-30. doi: 10.1016/j.canrad.2016.07.020. Epub 2016 Aug 10. Cancer Radiother. 2016. PMID: 27522185 French.
[Nasal cavity and paranasal sinus cancer].
Peyraga G, Lafond C, Pointreau Y, Giraud P, Maingon P. Peyraga G, et al. Among authors: lafond c. Cancer Radiother. 2016 Sep;20 Suppl:S99-S103. doi: 10.1016/j.canrad.2016.07.035. Epub 2016 Aug 12. Cancer Radiother. 2016. PMID: 27528562 French.
123 results